Cartesian President and CEO Murat Kalayoglu, M.D., Ph.D./Courtesy Cartesian Therapeutics
Cartesian Therapeutics is developing non-permanent cell therapies that can be used soon after diagnosis and address a wide range of diseases beyond cancer. The biotechs approach to cell engineering relies upon RNA rather than DNA to effect changes within the cells.
The benefit, Cartesian President and CEO Murat Kalayoglu, M.D., Ph.D. told BioSpace, is that our RNA approach, compared to a traditional DNA modification, offers an order of magnitude greater control over the therapeutic product and what happens when those cells are in the body. A high level of control is important if cell therapy is to be used in the treatment of either front-line cancer or in indications where the choice isnt between life and death.
RNA has a measurable half-life, Kalayoglu explained, so cell therapies driven by RNA arent permanent. The cells cant proliferate out of control. Consequently, Cartesian can develop cell therapy for newly diagnosed populations and for autoimmune, respiratory and inflammatory diseases, for example.
In contrast, conventional cell therapy involves engineered DNA, which makes a permanent change in the cell, he pointed out. When it is infused back into the patient and encounters its target, it proliferates and can lead to toxicities. For example, conventionally modified CAR-T therapies may proliferate so much they create cytokine release syndrome or neurotoxicity. Also, the cells may persist a very long time, increasing the risk of infection or transformation. Those risks are acceptable in life and death situations, but generally not acceptable in less dire situations.
Cartesians technology is known as the RNA Armory. Basically, with this platform, were using the cell as a factory and also as the vehicle to deliver RNA therapies directly to the targeted diseased tissue. It gives us the opportunity to engineer multiple RNA therapeutics into one cell type, Kalayoglu said.
The specific mechanism behind the RNA Armory is proprietary, but he said it enables tens to hundreds of billions of viable, highly-functional cells to be manufactured in a given production run. Thats important because adoptive cell therapy requires cells to be dosed into patients over time since the duration of therapy is finite. Conventional cell therapy, in contrast, relies on the cells to proliferate inside the body, often for a once-and-done therapy.
Cartesian has three programs in clinical development. The furthest along, Descartes-08, targets generalized myasthenia gravis, an autoimmune disease. Its composed of autologous CD8+ T-cells engineered with RNA-encoding chimeric antigen receptors (CARs) that bind B-cell maturation antigen (BCMA). The goal is to kill the plasma cell clones that produce the pathogenic autoantibodies. Earlier work showed a good safety profile and significant clinical improvements in patients after only a short duration of therapy. Theres a real opportunity to make a significant impact on the disease, Kalayoglusaid.
Likewise, Descartes-30 targets the web of inflammatory proteins known as neutrophil extracellular traps (NETs) that mediate ARDS. As yet, NETs are not addressed by any approved medications. Neutrophils try to control infections by putting out spiderwebs of NETs designed to capture virus particles and bacteria, but NETs also cause inflammation, Kalayoglu explained. That can become too much of a good thing, so Descartes-30 secretes two proteins that degrade NETs synergistically.
Descartes-30, is being used to treat acute respiratory distress syndrome (ARDS). Unlike Cartesians other programs, this one uses mesenchymal stem cells rather than T cells and is being developed as an allogeneic, off-the-shelf therapy. As such, it may have applications in treating COVID-19 patients and other NET-related diseases.
The remaining clinical program, Descartes-11, is being used to treat patients with multiple myeloma. Its currently enrolling participants in a Phase II clinical trial.
Each of these programs is based on the RNA Armory platform. That platform was developed for the companys own therapeutic pipeline, but Kalayoglu said he anticipates opportunities for out-licensing and partnerships. Well let clinical data drive those decisions.
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies. Using this platform, he suggested combination therapies may be able to be tested together, simultaneously, rather than developed independently and then combined and tested. The latter is very capital- and time-intensive, requiring three to five years and tens of millions of dollars, just to learn whether the combination works synergistically, Kalayoglu pointed out.
With RNA Armory, we can engineer those combination drugs directly into a cell, using the cell as a factory for producing those products and also as a vehicle to deliver them to the site of disease. Thats the future of cell therapy: combinations, Kalayoglu said.
There are some limitations, of course, in terms of the number of potential therapeutic combinations. He also acknowledged the usual safety concerns, which are amplified as you engineer additional therapeutics.
Nearly a year ago, researchers from Houston Methodist Research Institute indicated that RNA therapeutics will actualize personalized medicine, and will make the term undruggable obsolete, they wrote in Frontiers in Bioengineering and Biotechnology.
RNA cell therapy is a nascent field, Kalayoglu pointed out, where opportunities abound. Most of the work in this specific area tends to be conducted in academic centers. I hope others will follow our lead, and go beyond oncology, using adoptive cell therapy to treat a variety of indications.
Originally posted here:
- Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis - OncLive - January 16th, 2022
- Trial of Cell Therapy to Raise HbF Levels Showing Potential, But... - Sickle Cell Anemia News - January 16th, 2022
- What it's like in academic family medicine: Shadowing Dr. Rouhbakhsh - American Medical Association - January 16th, 2022
- The Fusion of mRNA and Immunotherapy - NEO.LIFE - January 16th, 2022
- Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference - The Bakersfield Californian - January 11th, 2022
- BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference -... - January 11th, 2022
- Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR - Yahoo Finance - January 11th, 2022
- Houston TX Diabetes Stem Cell Treatment Regenerative Medicine Therapy Launch - Digital Journal - January 9th, 2022
- Stem Cell Rejuvenation Center - January 9th, 2022
- Orthopedic Biomaterials Product Market: Hip implant product segment is anticipated to carry major share of the market - BioSpace - January 9th, 2022
- Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings - Business Wire - January 9th, 2022
- Jakubowiak Talks Daratumumab Quadruplet Therapy and the GRIFFIN Study at 2021 ASH - Cancer Network - January 9th, 2022
- Part 1: Benefit Shown With Transplant and Combination Therapy in Multiple Myeloma - Targeted Oncology - January 9th, 2022
- Notch Therapeutics' Peter Zandstra Appointed to the Order of Canada - Yahoo Finance - January 7th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults... - January 7th, 2022
- BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson's Disease - Yahoo Finance - January 7th, 2022
- Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy - Galveston County... - January 7th, 2022
- US FDA approves Phase 3 Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma - OncoZine - January 5th, 2022
- Alzheimer's Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases - PRNewswire - January 5th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy Designation To AlloVir's Posoleucel For The Treatment Of Adenovirus Infections In Adults And... - January 5th, 2022
- Protecting people with cancer from COVID-19: - EurekAlert - January 5th, 2022
- Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual JP Morgan Healthcare Conference - TheNewswire.ca - January 5th, 2022
- Placental Stem Cell Therapy Market to Surpass US$ 4.4 Bn by 2030, Underpinned by Enormous R&D in Cellular Therapies and Regenerative Medicine, Finds... - January 3rd, 2022
- LifeBank Chain Announces Upcoming Gene and Cell Collaboration Platform With Disrupt Blockchain Technologies - AsiaOne - January 3rd, 2022
- Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity - News-Medical.Net - January 3rd, 2022
- lodie Yung plunges into the undocumented underworld in 'The Cleaning Lady' - Entertainment Weekly News - January 3rd, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 2nd, 2022
- Curi Bio Closes $10M Series A in Oversubscribed Round - BioSpace - December 31st, 2021
- Bring in the bulldozers: Cynatas CEO on how heavyweight FujiFilm will turbocharge its ... - Stockhead - December 31st, 2021
- Questions on Quadruplets and CAR T Set to be Answered As Myeloma Paradigm Parses Out the Clinical Value of MRD - OncLive - December 31st, 2021
- Stem Cell Therapy NYC, Regenerative Medicine Injections ... - December 29th, 2021
- James Shapiro, MD: Insulin Production In T1D Patients After Stem Cell Therapy - MD Magazine - December 29th, 2021
- Global Automated and Closed Cell Therapy Processing Systems - GlobeNewswire - December 29th, 2021
- Bill would pave way for organ donation - Stabroek News - December 29th, 2021
- Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML - BioSpace - December 29th, 2021
- Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia/Lymphoma - Business Wire - December 29th, 2021
- 2021: The Year in Diabetes - Healthline - December 29th, 2021
- Covid infects kidneys and leads to scarring: Study - India New England - December 29th, 2021
- Fetal Gut May Have Insulin-Producing Cells That Shut Off at Birth - Medscape - December 29th, 2021
- Brem Looks at Multiple Treatments for Patients With DLBCL - Targeted Oncology - December 26th, 2021
- Delete Blood Cancer! How Content Creator Duo Abhi And Niyu Inspired Thousands To Give Someone Second... - The Logical Indian - December 25th, 2021
- The pathogenesis, natural history, and treatment of type 1 diabetes: time (thankfully) does not stand still - The Lancet - December 25th, 2021
- Ropinirole Proves Safe and Tolerable for Patients With ALS - Medscape - December 25th, 2021
- Major international research center may drive the development of future stem cell-based treatments - News-Medical.Net - December 19th, 2021
- Receiving CAR-T therapy sooner improves lymphoma survival, according to study published in New England Journal of Medicine - Newswise - December 19th, 2021
- Latest Cancer Research: CAR T to Liquid Biopsies - Healthline - December 19th, 2021
- Trials of stem cell therapy offer hope to childless women in Bangladesh - The Financial Express BD - December 19th, 2021
- UC San Diego Breaks Ground on Revitalization of Hillcrest Campus - UC San Diego Health - December 19th, 2021
- BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition -... - December 19th, 2021
- CAR-T Cell Therapy Continues to Impress in Myeloma Treatment - Curetoday.com - December 17th, 2021
- CAR-T therapy trials show promise for earlier use in lymphoma - BioPharma Dive - December 17th, 2021
- Cedars-Sinai researchers discover growth hormone in the colon that influences aging process - News-Medical.Net - December 17th, 2021
- Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors - Business Wire - December 17th, 2021
- BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of... - December 17th, 2021
- CAR T-Cell Therapy for Large B-Cell Lymphoma Who, When, and How? | NEJM - nejm.org - December 15th, 2021
- Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine... - December 15th, 2021
- AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders -... - December 15th, 2021
- Bioengineered skin breakthrough to revolutionise burns treatment - Medicine, Nursing and Health Sciences - Monash University - December 15th, 2021
- In Patients With Acute GVHD, First-Line Itolizumab Associated With High Rates of Clinical Response, Tolerability - Targeted Oncology - December 15th, 2021
- BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's Phase 3 Study for ALS in Muscle and Nerve - BioSpace - December 15th, 2021
- Flawed genetic switches could be at the origin of malformations or developmental diseases - News-Medical.net - December 15th, 2021
- BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing - BioSpace - December 9th, 2021
- Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT - December 9th, 2021
- What happened to Dolly the sheep? How long the first cloned adult mammal lived, and her legacy explained - iNews - December 9th, 2021
- It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India - ETHealthworld.com - December 9th, 2021
- For the 2nd time listed as the World's Top 2% scientists by Stanford University - Malaysiakini - December 9th, 2021
- Research offers a phylogenetic and ontogenetic overview of the primitive streak - News-Medical.net - December 7th, 2021
- New discoveries make steps toward lipoedema diagnosis and treatment - Mirage News - December 7th, 2021
- With its Parkinsons treatment, TreeFrog Therapeutics shows cell therapy is no longer science fiction - The Times Hub - December 7th, 2021
- The lung game: is hyperbaric oxygen therapy any good? - Financial Times - December 7th, 2021
- Irving Weissman Laboratory | Institute for Stem Cell ... - December 4th, 2021
- Nine Things To Know About Stem Cell Treatments - A Closer ... - December 4th, 2021
- Regenerative Medicine & Stem Cell Therapy Las Vegas ... - December 4th, 2021
- World AIDS Day: is a cure for HIV finally in sight? - Thomson Reuters Foundation - December 4th, 2021
- New genetic technology for gene expression analysis of cancer cells - News-Medical.net - December 4th, 2021
- Stem Cell Therapy Restores Insulin Production in Patients with Type 1 Diabetes - MD Magazine - December 4th, 2021
- It takes guts to make a heart - EurekAlert - December 4th, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - BioSpace - December 4th, 2021
- The Intramural Research Program at the Abu Dhabi Stem Cell Center (ADSCC) Signs a Letter of Intent to Collaborate with the Division of Intramural... - December 4th, 2021
- TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition - GlobeNewswire - December 4th, 2021